Hello everyone! Thank you to all of the authors and experts for their participation in this forum. I am looking forward to our discussion on the article titled "Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease" over the next week. Let's jump right in:
This study was a large-scale, randomized trial where the rates of target-lesion failure at 1 year were 1.7 percentage points higher in the Absorb group than in the Xience group. This was a nonsignificant difference that met the study criteria for noninferiority. What are the initial thoughts and takeaway points from these study results? Was the 1-year time point too short to identify benefits?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.